Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hexyon immunogenicity and safety in preterm infants
2018-004581-34Phase 4Active
- Sponsor
- Fundación Instituto Hispalense de Pediatría
- Start
- Jan 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Hexyon in Vaccine-preventable disease (VPD), sponsored by Fundación Instituto Hispalense de Pediatría. Primary endpoints: Seroprotection or vaccine response after second dose and Seroprotection or vaccine response after end of vaccination. Started Jan 2019; status: active.
02
Drugs
Hexyon
03
Conditions
Vaccine-preventable disease (VPD)
Beyond the preview
Go deeper on 2018-004581-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004581-34.